These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20652971)

  • 41. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
    Burger R; Le Gouill S; Tai YT; Shringarpure R; Tassone P; Neri P; Podar K; Catley L; Hideshima T; Chauhan D; Caulder E; Neilan CL; Vaddi K; Li J; Gramatzki M; Fridman JS; Anderson KC
    Mol Cancer Ther; 2009 Jan; 8(1):26-35. PubMed ID: 19139110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
    Lin J; Wu Y; Yang D; Zhao Y
    Oncol Rep; 2013 Aug; 30(2):731-8. PubMed ID: 23708869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
    Khong T; Spencer A
    Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
    Feng N; Luo J; Guo X
    Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
    Zhang T; Jiang B; Zou ST; Liu F; Hua D
    World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
    Tantawy MA; El-Sherbeeny NA; Helmi N; Alazragi R; Salem N; Elaidy SM
    Mol Cell Biochem; 2020 Jun; 469(1-2):143-157. PubMed ID: 32356241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
    Yang CC; Lin HP; Chen CS; Yang YT; Tseng PH; Rangnekar VM; Chen CS
    J Biol Chem; 2003 Jul; 278(28):25872-8. PubMed ID: 12738789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma.
    Amet R; Previtali V; Mihigo HB; Sheridan E; Brophy S; Hante NK; Santos-Martinez MJ; Hayden PJ; Browne PV; Rozas I; McElligott AM; Zisterer DM
    Life Sci; 2022 Feb; 290():120236. PubMed ID: 34953891
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
    Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
    Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
    Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.
    Jazirehi AR; Bonavida B
    Mol Cancer Ther; 2004 Jan; 3(1):71-84. PubMed ID: 14749477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma.
    Ramakrishnan V; Painuly U; Kimlinger T; Haug J; Rajkumar SV; Kumar S
    Leukemia; 2014 Jul; 28(7):1519-28. PubMed ID: 24402161
    [TBL] [Abstract][Full Text] [Related]  

  • 53. As
    Wu D; Dong W; Fang K; Wang M
    Technol Cancer Res Treat; 2019; 18():1533033819896806. PubMed ID: 31868118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
    Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
    Oncogene; 2010 Feb; 29(8):1190-202. PubMed ID: 19935717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased lncRNA HOTAIR expression promotes the chemoresistance of multiple myeloma to dexamethasone by regulating cell viability and apoptosis by mediating the JAK2/STAT3 signaling pathway.
    Guan R; Wang W; Fu B; Pang Y; Lou Y; Li H
    Mol Med Rep; 2019 Oct; 20(4):3917-3923. PubMed ID: 31485665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
    Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
    Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
    Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
    Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.